Semaglutide Improves Reward-Based Motivation in Patients With Major Depressive Disorder

Targeting the Neurobiology of Motivation in Depressive Disorders

Major depressive disorder is frequently characterized by profound deficits in reward processing and motivation that often persist despite standard antidepressant therapy. While glucagon-like peptide-1 receptor agonists are established treatments for type 2 diabetes and obesity, evidence suggests these agents also modulate central reward circuits [1, 2]. Clinical interest has expanded to their potential role in treating cognitive dysfunction and metabolic disturbances associated with psychiatric conditions, particularly those exacerbated by antipsychotic medications [3, 4]. Furthermore, bidirectional communication within the microbiota-gut-brain axis (the signaling network between the gastrointestinal tract and the central nervous system) suggests that metabolic hormones regulate complex behaviors and glial functions, which are the activities of non-neuronal cells that maintain brain homeostasis [5]. A randomized clinical trial of 72 participants recently demonstrated that 14 mg of oral semaglutide significantly improved measures of motivation by reducing the perceived cost of effort relative to reward (P =.02), suggesting a potential role for these agents in treating the motivational deficits of clinical depression [6].

Trial Design and Patient Characteristics

The study was a 16-week, double-blind, placebo-controlled, parallel-group randomized clinical trial conducted at the Mood Disorders Psychopharmacology Unit within the University Health Network in Toronto. Researchers recruited a total of 72 participants who met the diagnostic criteria for major depressive disorder and had a body mass index of 25 or higher, a common clinical presentation given the frequent overlap between mood disorders and metabolic dysfunction. Enrollment occurred between March 14, 2022, and July 26, 2024, with subsequent data analysis performed from January 7, 2025, through February 3, 2025. This trial (ClinicalTrials.gov Identifier: NCT04466345) investigated the effects of glucagon-like peptide-1 receptor activation on motivated behavior in a clinical population. Participants were randomized in a 1:1 ratio to receive either 14 mg of oral semaglutide (n = 35) or a placebo (n = 37) as an adjunct to their treatment as usual. To manage gastrointestinal tolerability, the semaglutide dose was initiated at 4 mg and increased using a 4-week dose-escalation regimen until the maintenance dose was reached. The semaglutide cohort had a mean age of 38.17 years (standard deviation of 11.79) and included 18 female participants (51.4 percent). The placebo group was demographically comparable, with a mean age of 40.27 years (standard deviation of 9.32) and 19 female participants (51.3 percent). These baseline characteristics ensured that the two groups were well-balanced for the secondary analysis of reward-related dysfunction.

Quantifying Motivation via Effort-Based Decision-Making

The rationale for this investigation stems from a growing body of preclinical and clinical studies indicating that the activation of glucagon-like peptide-1 receptors affects reward processes in the brain. While these receptors are well-known for their role in glucose homeostasis and satiety, their presence in mesolimbic reward circuits suggests they may also modulate the drive to seek incentives. Despite this biological link, no previous study has evaluated whether a glucagon-like peptide-1 receptor agonist affects motivated behavior in individuals with major depressive disorder in a randomized clinical trial. This study addressed that gap by specifically assessing the effects of semaglutide on reward-related dysfunction in a population with major depressive disorder and a body mass index of 25 or higher. To objectively measure these behavioral changes, the researchers utilized the Effort-Expenditure for Rewards Task as the preregistered outcome of this secondary analysis. This validated behavioral paradigm requires participants to make repeated choices between a low-effort task for a small, fixed monetary reward and a high-effort task for a larger, variable reward. By manipulating the probability of receiving the reward and the magnitude of the payout, the task allows for a quantitative assessment of how much physical effort a patient is willing to exert for a specific expected value. This tool is particularly relevant for clinicians because it provides a laboratory-based proxy for the motivational deficits and anhedonia frequently observed in patients with major depressive disorder, translating subjective complaints of fatigue into measurable data.

Reduced Effort Discounting and Enhanced Reward Sensitivity

The analysis of the Effort-Expenditure for Rewards Task revealed that semaglutide-treated participants exhibited a pattern of increased willingness to exert physical efforts with higher expected values of reward. This behavioral shift was statistically significant, as evidenced by a treatment by visit by expected value interaction (χ2 = 12.024; P = .02). These findings suggest that the medication alters the decision-making framework patients use when weighing the benefits of a reward against the physical exertion required to obtain it, potentially addressing the profound amotivation that characterizes many depressive episodes. To further understand the mechanisms behind these behavioral changes, the researchers employed computational modeling (a mathematical method used to simulate and analyze the decision-making processes underlying behavior). This analysis indicated that semaglutide's effects on choice behavior were a result of reduced effort discounting. Effort discounting is a cognitive process where the perceived value of a reward decreases as the physical or mental effort required to obtain it increases. Specifically, sensitivity to effort was significantly reduced by treatment with semaglutide (β = -1.737; P = .03). This reduction in sensitivity suggests that patients receiving the medication did not find the physical tasks as deterrent as those in the placebo group, effectively lowering the barrier to goal-directed activity. Notably, the effect of the medication appeared specific to the physical cost of the task rather than the likelihood of success. There was no treatment effect on sensitivity to probability (β = -0.776; P = .51), indicating that semaglutide did not alter how patients perceived the risk or chance of receiving a reward. Ultimately, treatment with semaglutide significantly improved measures of motivation in patients with major depressive disorder by reducing the perceived cost of effort relative to the monetary reward. For the practicing physician, these results provide a quantitative basis for how glucagon-like peptide-1 receptor agonists might address the core motivational deficits that often complicate the management of depression, raising the prospect of using metabolic therapies to target specific neurobiological symptoms in psychiatric care.

References

1. McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature Medicine. 2025. doi:10.1038/s41591-025-03978-z

2. Liu L, Li Z, Ye W, et al. Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine. 2024. doi:10.1016/j.eclinm.2024.103020

3. Bak M, Campforts B, Domen P, Amelsvoort TV, Drukker M. Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica. 2024. doi:10.1111/acps.13734

4. Vasiliu O. Therapeutic management of atypical antipsychotic‑related metabolic dysfunctions using GLP‑1 receptor agonists: A systematic review. Experimental and Therapeutic Medicine. 2023. doi:10.3892/etm.2023.12054

5. Loh JS, Mak WQ, Tan L, et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01743-1

6. Gill H, Badulescu S, Shah H, et al. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.. JAMA psychiatry. 2026. doi:10.1001/jamapsychiatry.2026.0594